ArticleJournal of translational medicine2026
Analysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid-immune cell coculture.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of conventional αβ T cell-based immunotherapies is often limited by tumor immune evasion. γδ T cells can bypass these limitations through MHC-independent tumor recognition, but their function within the tumor microenvironment (TME) remains poorly characterized due to a lack of relevant preclinical models. This study aims to establish a patient-derived tumor organoid-immune cell coculture system to evaluate γδ T-cell reactivity and cytotoxicity in a human-relevant TME (n = 10 PDTO lines; n = 3 independent experiments).
methodsWe developed an innovative coculture system—believed to be the first to integrate patient-derived tumor organoids (PDTOs) and autologous tumor-infiltrating lymphocytes (TILs) or healthy donor-derived allogeneic Vγ9Vδ2 T cell. T-cell activation was quantified by comparing CD137 expression on γδ T cells versus CD4+ and CD8+ T cells via flow cytometry after coculture. The cytotoxicity of Vγ9Vδ2 T cells was evaluated at various effector-to-target (E:T) ratios using a live-cell imaging assay to track BCO infiltration and apoptosis over 24 hours. Secreted effector molecules (IFN-γ, granzyme B, perforin) were measured from coculture supernatants using a cytometric bead array.
resultsBaseline analysis revealed that γδ T cells represent the most reactive subset within expanded TILs, with 12.3% expressing CD137 compared to 3.49% of CD8+ T cells (p = 0.0118). Notably, autologous BCO–TIL coculture preferentially enhanced γδ T-cell activation, reaching 24.85% CD137+—a frequency significantly higher than that of CD8 (9.15%, p = 0.0062) and CD4 (9.99%) subsets. The net increase in CD137 positivity for γδ T cells was more than double that of CD8 T cells (12.55% vs. 5.66%, p = 0.0467). Allogeneic Vγ9Vδ2 T cells demonstrated significant, dose-dependent cytotoxicity against BCOs (p < 0.0001). Maximal cell death (RFU fold-change: 5.2 ± 0.5) was achieved at an effector-to-target (E:T) ratio of 10:1 (p < 0.0001). This cytotoxic efficacy was highly correlated with the secretion of lytic effectors, including IFN-γ ( > 1000 pg/mL; p< 0.001), granzyme B ( > 2000 pg/mL), and perforin ( > 350 pg/mL).
conclusionOur findings demonstrate that 3D autologous coculture leads to the preferential stimulation of γδ T cells, establishing them as a primary reactive subset capable of bypassing MHC-restriction bottlenecks. The potent dismantling of tumor architecture by allogeneic Vγ9Vδ2 T cells, supported by high-resolution kinetic and cytokine data, substantiates their development as “off-the-shelf” therapies. Collectively, this platform provides a standardized, high-fidelity engine for the rapid preclinical assessment of next-generation cellular immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.